~33 spots leftby May 2028

Cord Blood Transplant for Blood Cancers

Recruiting in Palo Alto (17 mi)
+6 other locations
IP
Overseen byIoannis Politikos, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
Must not be taking: Checkpoint inhibitors
Disqualifiers: Myelofibrosis, CNS disease, HIV, others
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get specific guidance.

What data supports the effectiveness of this treatment for blood cancers?

Research shows that umbilical cord blood transplantation (using stem cells from umbilical cord blood) is a promising treatment for blood cancers, especially when other treatments have failed. It has advantages like better matching and lower risk of complications compared to other stem cell sources, and studies have shown it can lead to better disease control and survival rates.12345

Is cord blood transplant generally safe for humans?

Cord blood transplants, like other stem cell transplants, can have serious side effects, but recent advances have made them less toxic. Studies show that using less intense conditioning treatments can reduce complications, although some risks remain, such as infections and organ-related side effects.678910

How is cord blood transplant treatment different from other treatments for blood cancers?

Cord blood transplant treatment is unique because it uses stem cells from umbilical cord blood, which can be a suitable option for patients who do not have a matched donor in their family or the unrelated registry. This approach can reduce the risk of severe graft-versus-host disease and is particularly beneficial for patients from diverse ethnic backgrounds who may struggle to find a fully matched donor.311121314

Research Team

IP

Ioannis Politikos, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with various high-risk blood cancers, including different types of leukemia and lymphoma. Participants must meet specific criteria such as being in a certain phase of remission, having adequate organ function, and not having had certain previous treatments like stem cell transplants within the last year.

Inclusion Criteria

I have a high-risk form of MDS or MPD.
My Non-Hodgkin lymphoma is at high risk of getting worse if not in remission.
My organs are functioning well and I can do most activities.
See 6 more

Exclusion Criteria

I have been diagnosed with myelofibrosis or another cancer that affects my bone marrow.
My brain or spinal cord cancer is still visible on scans.
I had a stem cell transplant from my own cells within the last year.
See 10 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Conditioning Treatment

Participants receive standard chemotherapy and total body irradiation therapy to prepare for the transplant

1-2 weeks

Transplantation

Infusion of the double-unit cord blood graft

1 day
Inpatient stay for transplantation

Post-Transplant Monitoring

Participants are monitored for side effects, disease relapse, GVHD, and immune system recovery

Up to 45 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Treatment Details

Interventions

  • Conditioning Chemotherapy (Chemotherapy)
  • Cord blood graft (Stem Cell Transplant)
Trial OverviewThe study tests an 'optimized' cord blood transplant (CBT) process developed by MSK. It includes evaluation methods, conditioning chemotherapy, total body irradiation before the transplant, and post-transplant care to assess side effects, disease relapse rates, graft-versus-host disease (GVHD), and immune recovery.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Cord Blood TransplantExperimental Treatment2 Interventions
Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.

Conditioning Chemotherapy is already approved in Canada, Japan, China, Switzerland for the following indications:

🇨🇦
Approved in Canada as Chemotherapy for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Multiple myeloma
🇯🇵
Approved in Japan as Chemotherapy for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Multiple myeloma
🇨🇳
Approved in China as Chemotherapy for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Multiple myeloma
🇨🇭
Approved in Switzerland as Chemotherapy for:
  • Blood cancers
  • Leukemia
  • Lymphoma
  • Multiple myeloma

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+
Lisa M. DeAngelis profile image

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers profile image

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Findings from Research

Umbilical cord blood transplantation (UCBT) using an improved myeloablative conditioning regimen (TBI/Ara-c/CY) resulted in 100% engraftment among 40 adult patients with hematological malignancies, demonstrating its efficacy in establishing donor cell engraftment.
The treatment showed a two-year overall survival rate of 58.8%, with lower relapse rates and chronic graft-versus-host disease (GVHD) occurrences in high-risk and advanced patients, indicating a favorable safety profile and potential benefits for these challenging cases.
[Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].Sun, ZM., Liu, HL., Geng, LQ., et al.[2012]
Umbilical cord blood (CB) transplantation offers significant advantages over traditional bone marrow transplantation, including better matching, quicker availability, and reduced risk of graft-versus-host disease, making it a promising option for patients with hematological malignancies.
CB-derived T cells can be expanded and modified for enhanced immunotherapy, and combining these with vaccination strategies may lead to more effective treatments against tumors.
Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives.Lo Presti, V., Nierkens, S., Boelens, JJ., et al.[2019]
Umbilical cord blood transplantation (CBT) has seen significant advancements over the past 20 years, improving myeloid and platelet engraftment rates, particularly through strategies like double CBT and ex-vivo graft engineering.
Despite these improvements, delayed immune reconstitution remains a major challenge, especially in adult recipients, leading to increased risks of infections; ongoing research is focused on enhancing T cell recovery and preserving thymopoiesis to further improve patient outcomes.
Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution.Escalón, MP., Komanduri, KV.[2019]

References

[Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies]. [2012]
Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives. [2019]
Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. [2019]
Conditioning with 10 Gy Total Body Irradiation, Cyclophosphamide, and Fludarabine without ATG Is Associated with Improved Outcome of Cord Blood Transplantation in Children with Acute Leukemia. [2021]
Umbilical cord blood transplantation: a maturing technology. [2016]
Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review. [2019]
Managing the toxicity of hematopoietic stem cell transplant. [2005]
Aims of conditioning. [2019]
Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children. [2022]
[Patient treated with chemotherapy. Alarm signs requiring immediate intervention]. [2006]
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. [2013]
12.United Statespubmed.ncbi.nlm.nih.gov
Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. [2021]
[Present state of cord-blood stem cell transplantation]. [2007]
Update on umbilical cord blood transplantation. [2019]